background and aims: the aim of this study was the modeling of the incidence rates of colorectal, breast and prostate cancers using a shared component model in order to explore the spatial pattern of their shared risk factors (i.e., obesity and low physical activity) affecting on cancer incidence, and also to estimate the relative weight of these shared components. methods: in this study, the ...

slug (snai2), a regulator of epithelial-to-mesenchymal transition (emt), is a zinc finger transcription factor involved in neurulation. intriguingly, snai2 gene expression has been linked to the aggressiveness of neuroblastoma, melanoma and lung, colon, ovarian and breast carcinoma. of note, many metastatic cancers recapitulate emt to enhance cell motility and invasion. moreover, metastasis is ...

Lymph node (LN) metastasis is considered an important prognostic factor in patients with prostate cancer. The aim of this study was to determine the rate of LN metastasis among an Iranian population who underwent radical prostatectomy (RP) with pelvic LN dissection (PLND). In a retrospective review of medical records, 450 RP cases were included and the data on LN metastasis were extracted from ...

treatment of bone metastases comprises over 10% of the workload of a radiation-oncology center. bone metastases produce severe pain and immobility, necessitate narcotic use, and reduce the quality of life. a good palliative treatment must be complete, free from side effects and fast; thus we decided to evaluate strontium-89 (89sr) effectivity for palliation of breast and prostate cancer bone me...

The immune checkpoint inhibitor (ICI) is a promising strategy for treating cancer. However, the efficiency of ICI monotherapy limited, which could be mainly attributed to tumor microenvironment “cold” tumor. Prostate cancer, type most common cancer affecting men’s health. Radiotherapy regarded as one effective prostate treatments. In era therapy, enhanced antigen presentation and cell infiltrat...

Early detection of prostate cancer using glycosylated biomarker sensors.

A special form of prostate cancer is non-metastatic castration-resistant cancer. Patients with this have rising prostate-specific antigen and castrate testosterone levels, no radiological findings metastatic disease on computed tomography bone scan. The phase III trials demonstrated apalutamide, darolutamide or enzalutamide to be associated a significantly longer median metastasis-free survival...

Introduction Transient decrease in serum prostate-specific antigen level can occur after abiraterone acetate withdrawal male patient with metastatic castration-resistant prostate cancer. Here, we report a case of syndrome transient progression to disease while using upfront therapy for high-risk Case presentation A 73-year-old man hormone-sensitive cancer multiple bone metastases (prostate-spec...